Denali Therapeutics Inc. Operating Lease Cost
Denali Therapeutics Inc. (DNLI) reported Operating Lease Cost of $1.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Denali Therapeutics Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.82M, a 3.80% decline year-over-year.
- Denali Therapeutics Inc. operating lease, cost for the quarter ending 2026-03-31 was $1.85M, a 2.11% decline year-over-year.
- Denali Therapeutics Inc. operating lease, cost for the quarter ending 2025-12-31 was $1.90M, a 36.43% increase year-over-year.
- Denali Therapeutics Inc. operating lease, cost for the quarter ending 2025-09-30 was $1.90M, a 0.00% change year-over-year.
- Denali Therapeutics Inc. operating lease, cost for fiscal 2025 was $7.59M, a 5.65% increase from fiscal 2024.
- Denali Therapeutics Inc. operating lease, cost for fiscal 2024 was $7.19M, a 9.95% decline from fiscal 2023.
- Denali Therapeutics Inc. operating lease, cost for fiscal 2023 was $7.98M, a 0.21% decline from fiscal 2022.
- Denali Therapeutics Inc. operating lease, cost for fiscal 2022 was $8.00M, a 27.27% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.82M 10-Q · filed 2026-08-06 | $3.67M 10-Q · filed 2026-08-06 | $5.57M derived: sum of 3 quarters · filed 2026-08-06 | $7.47M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $1.85M 10-Q · filed 2026-05-07 | $3.75M derived: sum of 2 quarters · filed 2026-05-07 | $5.65M derived: sum of 3 quarters · filed 2026-05-07 | $7.54M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.79M derived: sum of 2 quarters · filed 2026-02-26 | $5.69M derived: sum of 3 quarters · filed 2026-08-06 | $7.59M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $1.90M 10-Q · filed 2025-11-06 | $3.79M derived: sum of 2 quarters · filed 2026-08-06 | $5.70M 10-Q · filed 2025-11-06 | $7.08M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $1.89M 10-Q · filed 2026-08-06 | $1.90M 10-Q · filed 2025-08-11 | $3.79M 10-Q · filed 2026-08-06 | $3.80M 10-Q · filed 2025-08-11 | $5.17M derived: sum of 3 quarters · filed 2026-08-06 | $7.08M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.89M 10-Q · filed 2026-05-07 | $1.90M 10-Q · filed 2025-05-06 | $3.28M derived: sum of 2 quarters · filed 2026-05-07 | $5.18M derived: sum of 3 quarters · filed 2026-05-07 | $7.08M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.29M derived: sum of 2 quarters · filed 2026-02-26 | $5.19M derived: sum of 3 quarters · filed 2026-02-26 | $7.19M 10-K · filed 2026-02-26 | $7.20M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-06 | $3.80M derived: sum of 2 quarters · filed 2025-11-06 | $5.80M 10-Q · filed 2025-11-06 | $7.68M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $1.90M 10-Q · filed 2025-08-11 | $3.10M 10-Q · filed 2024-08-01 | $3.90M 10-Q · filed 2025-08-11 | $6.20M 10-Q · filed 2024-08-01 | $5.78M derived: sum of 3 quarters · filed 2026-02-26 | $7.68M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-06 | $2.90M 10-Q · filed 2024-05-07 | $3.88M derived: sum of 2 quarters · filed 2026-02-26 | $5.78M derived: sum of 3 quarters · filed 2026-02-26 | $9.08M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.78M derived: sum of 2 quarters · filed 2026-02-26 | $7.08M derived: sum of 3 quarters · filed 2026-02-26 | $7.98M 10-K · filed 2026-02-26 | $12.40M 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $1.90M 10-Q · filed 2024-11-06 | $3.20M 10-Q · filed 2023-11-07 | $5.20M derived: sum of 2 quarters · filed 2024-11-06 | $6.10M 10-Q · filed 2024-11-06 | $9.40M 10-Q · filed 2023-11-07 | $7.40M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $3.30M 10-Q · filed 2024-08-01 | $6.20M 10-Q · filed 2024-08-01 | $5.50M derived: sum of 3 quarters · filed 2025-02-27 | $8.80M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $2.90M 10-Q · filed 2024-05-07 | $2.20M derived: sum of 2 quarters · filed 2025-02-27 | $5.50M derived: sum of 3 quarters · filed 2025-02-27 | $8.10M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.60M derived: sum of 2 quarters · filed 2025-02-27 | $5.20M derived: sum of 3 quarters · filed 2025-02-27 | $8.00M 10-K · filed 2025-02-27 | $12.00M 10-K · filed 2024-02-28 | |||
| 2022-09-30 | $3.30M 10-Q · filed 2023-11-07 | $5.90M derived: sum of 2 quarters · filed 2023-11-07 | $8.70M 10-Q · filed 2023-11-07 | |||||
| 2022-06-30 | $2.60M 10-Q · filed 2023-08-08 | $5.50M 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | $2.80M 10-Q · filed 2023-05-08 | |||||||
| 2021-12-31 | $11.00M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |